Even among young women with HR+ breast cancer treated with OFS with a GnRH agonist, obese patients are more likely to experience elevated estradiol levels, and incomplete OFS may underlie a higher recurrence risk in this setting as well29,30. The gene discussed is GNRH1; the disease is breast cancer.